BUZZ-Maze Therapeutics jumps on early data for kidney disease drug
Shares of Maze Therapeuticssurged 35% to $21.77 in premarket trading following positive early-stage trial results for its oral drug MZE782, which targets the SLC6A19 protein. The trial demonstrated significant increases in phenylalanine and glutamine excretion without serious side effects. The company plans to initiate mid-stage studies in 2026 for phenylketonuria and chronic kidney disease. Year-to-date, the stock is up 0.4%.
Shares of drug developer Maze Therapeutics (MAZE.O) rise 35% to $21.77 premarket
Company says its experimental oral drug, MZE782, showed strong results in an early-stage trial
The drug, which blocks a protein called SLC6A19, led to a sharp increase in the amounts of phenylalanine and glutamine excreted in urine
Company says it plans to begin mid-stage studies in 2026 for phenylketonuria, a rare genetic disorder, and chronic kidney disease, a long-term condition affecting kidney function
No serious side-effects were reported in the study, which tested the drug in 112 healthy adults, company says
As of last close, stock up 0.4% YTD
